
A November 10 headline asked whether argenx shares already reflect the value of its announced US$1.15 billion acquisition.
The headline followed November 9 reports that argenx had agreed to acquire Unnatural Products. The deal would add a peptide discovery engine and broaden the company’s immunology capabilities. The available headlines do not provide further deal terms.
Investor takeaway: The acquisition prompted the “fully priced” question. The supplied figures show a recent share price of US$960.04 and a 17.32% gain over one month.
argenx NV ADR
ARGX.US
ARGX.US
argenx NV ADR
Market cap
$60.37B
P/E
33.3x
52W high
$1072.75
52W low
$661.85
1W change
+3.54%
Beta
-0.06
Analyst Price Targets
Based on 24 analysts covering ARGX · as of Nov 16, 2026
Wall Street analysts forecast ARGX stock price to rise 19.2% over the next 12 months.
Consensus
Buy4.46 / 5.00
Avg. Target
C$1144.74
+19.2% Upside
Previously C$1147.35 on Nov 2, 2026
Current Price
C$960.04
Last close
Analyst Breakdown (24 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ARGX's historical volatility
30-Day Vol
51.5%
Annualized
90-Day Vol
46.7%
Annualized
Trend (90d)
-32.8%
Annualized drift
90d Mean
C$853.79
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$923.23 | C$773.05 – C$1102.59 |
| 60 trading days | C$887.83 | C$690.70 – C$1141.23 |
| 90 trading days | C$853.79 | C$627.78 – C$1161.18 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
US$1.15 billion deal; US$960.04 last close
The US$1.15 billion figure is the value cited in the acquisition headlines. Separately, argenx’s last close was US$960.04. Shares were up 17.32% over one month and 14.29% year to date.
Bull case
The acquisition would add a peptide discovery engine and broaden argenx’s immunology capabilities, giving the deal a stated strategic rationale.
Bear case
The November 10 headline raises a valuation question. Shares had gained 17.32% over the preceding month, according to the supplied performance figures.
The acquisition prompted the valuation question
On November 9, headlines reported that argenx would acquire Unnatural Products for up to US$1.15 billion. Another described the deal as a way to add a peptide discovery engine and broaden the company’s immunology capabilities.
The next day, a headline questioned whether argenx shares already looked fully priced despite the acquisition. The available headlines do not state the payment structure or expected closing date. Investors can follow ARGX.US on the argenx stock page.
Shares had gained 17.32% over one month
argenx’s last close was US$960.04. The supplied figures show a 2.17% decline over one day, a 3.54% gain over one week, a 17.32% gain over one month and a 14.29% gain year to date.
Latest volume was 5,333 shares, compared with a 20-day average of 420,013. The reported volume ratio was 0.54x. The share price was within its supplied 52-week range of US$661.85 to US$1,072.75, at 73% of that range. These figures provide trading context but do not show how much of the recent price movement was related to the acquisition.
Deal execution is the next event to follow
The acquisition’s stated aim is to add peptide discovery capabilities and broaden argenx’s immunology work. Investors can watch for updates on the transaction’s progress and how the acquired capabilities fit that aim.
The available company-news headlines cover the announcement and its rationale, but provide no completion timeline or further implementation details. For company and share information, see the argenx listing page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.

Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.


